NEIS JOHN 4
4 · Cellectar Biosciences, Inc. · Filed Mar 16, 2021
Insider Transaction Report
Form 4
NEIS JOHN
Director
Transactions
- Sale
Series A Warrants
2021-03-12$0.27/sh−41,155$10,980→ 193,587 totalExercise: $30.40From: 2016-04-20Exp: 2021-04-20→ Common Stock (4,115 underlying) - Sale
Series A Warrants
2021-03-16$0.31/sh−100,515$31,069→ 81,872 totalExercise: $30.40From: 2016-04-20Exp: 2021-04-20→ Common Stock (10,051 underlying) - Sale
Series A Warrants
2021-03-15$0.27/sh−11,200$2,970→ 182,387 totalExercise: $30.40From: 2016-04-20Exp: 2021-04-20→ Common Stock (1,120 underlying)
Footnotes (3)
- [F1]The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.2648 and $0.27, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.265 and $0.2666, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The price reported is a weighted average price. These warrants were sold in multiple transactions at prices ranging from $0.28 and $0.34, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants sold at each separate price within the ranges set forth in footnote (3) to this Form 4.